These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 8750624)
1. Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation. Varterasian M; Ratanatharathorn V; Uberti JP; Karanes C; Abella E; Momin F; Kasten-Sportes C; Al-Katib A; Lum L; Heilbrun LK Leuk Lymphoma; 1995 Dec; 20(1-2):59-65. PubMed ID: 8750624 [TBL] [Abstract][Full Text] [Related]
2. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928 [TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma. Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091 [TBL] [Abstract][Full Text] [Related]
4. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609 [TBL] [Abstract][Full Text] [Related]
5. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Dann EJ; Daugherty CK; Larson RA Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751 [TBL] [Abstract][Full Text] [Related]
6. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314 [TBL] [Abstract][Full Text] [Related]
7. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma. Fitoussi O; Simon D; Brice P; Makke J; Scrobohaci ML; Bibi Triki T; Hennequin C; Fermé C; Gisselbrecht C Bone Marrow Transplant; 1999 Oct; 24(7):747-55. PubMed ID: 10516678 [TBL] [Abstract][Full Text] [Related]
8. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523 [TBL] [Abstract][Full Text] [Related]
9. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921 [TBL] [Abstract][Full Text] [Related]
10. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. Darrington DL; Vose JM; Anderson JR; Bierman PJ; Bishop MR; Chan WC; Morris ME; Reed EC; Sanger WG; Tarantolo SR J Clin Oncol; 1994 Dec; 12(12):2527-34. PubMed ID: 7989926 [TBL] [Abstract][Full Text] [Related]
11. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Majolino I; Pearce R; Taghipour G; Goldstone AH J Clin Oncol; 1997 Feb; 15(2):509-17. PubMed ID: 9053472 [TBL] [Abstract][Full Text] [Related]
12. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. Lazarus HM; Rowlings PA; Zhang MJ; Vose JM; Armitage JO; Bierman PJ; Gajewski JL; Gale RP; Keating A; Klein JP; Miller CB; Phillips GL; Reece DE; Sobocinski KA; van Besien K; Horowitz MM J Clin Oncol; 1999 Feb; 17(2):534-45. PubMed ID: 10080597 [TBL] [Abstract][Full Text] [Related]
13. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer]. Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945 [TBL] [Abstract][Full Text] [Related]
14. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. Weaver CH; Petersen FB; Appelbaum FR; Bensinger WI; Press O; Martin P; Sandmaier B; Deeg HJ; Hansen JA; Brunvand M J Clin Oncol; 1994 Dec; 12(12):2559-66. PubMed ID: 7989929 [TBL] [Abstract][Full Text] [Related]
15. Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma. Lenain C; Dumontet C; Gargi T; Chassagne C; Berger F; Perol D; Garnier M; Coiffier B; Blay JY Hematol J; 2004; 5(5):403-9. PubMed ID: 15448666 [TBL] [Abstract][Full Text] [Related]
16. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle. André M; Henry-Amar M; Pico JL; Brice P; Blaise D; Kuentz M; Coiffier B; Colombat P; Cahn JY; Attal M; Fleury J; Milpied N; Nedellec G; Biron P; Tilly H; Jouet JP; Gisselbrecht C J Clin Oncol; 1999 Jan; 17(1):222-9. PubMed ID: 10458237 [TBL] [Abstract][Full Text] [Related]
17. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247 [TBL] [Abstract][Full Text] [Related]
18. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. Reece DE; Barnett MJ; Connors JM; Fairey RN; Fay JW; Greer JP; Herzig GP; Herzig RH; Klingemann HG; LeMaistre CF J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637 [TBL] [Abstract][Full Text] [Related]
19. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. Sharp JG; Kessinger A; Mann S; Crouse DA; Armitage JO; Bierman P; Weisenburger DD J Clin Oncol; 1996 Jan; 14(1):214-9. PubMed ID: 8558200 [TBL] [Abstract][Full Text] [Related]
20. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis. Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]